Results 211 to 220 of about 15,266 (342)

Changes in the Use of Telephone Follow-ups among Patients with Urologic Malignancies in Japan. [PDF]

Ann Clin Epidemiol
Fujino K, Masumori N, Hinotsu S.
europepmc   +1 more source

Survivorship Post‐Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: A Systematic Review

International Journal of Urology, EarlyView.
ABSTRACT Introduction Retroperitoneal lymph node dissection (RPLND) may be considered after chemotherapy or as primary treatment in patients with metastatic testicular cancer. We aimed to perform a systematic review to analyze outcomes in survivors across the domains of sexual, physical, and psychological function.
Gavin G. Calpin, Niall J. O'Sullivan, Cian Hehir, Arun Z. Thomas, Rowan G. Casey   +4 more
wiley   +1 more source

Relationship Between Loss of Y Chromosome and Urologic Cancers: New Future Perspectives. [PDF]

Cancers (Basel)
Russo P, Bizzarri FP, Filomena GB, Marino F, Iacovelli R, Ciccarese C, Boccuto L, Ragonese M, Gavi F, Rossi F, Savoia C, Suraci PP, Falabella R, Pandolfo SD, Napolitano L, Leoni C, Trevisan V, Palermo G, Racioppi M, Sacco E, Muselaers S, Foschi N.   +21 more
europepmc   +1 more source

Impact of Estimated Glomerular Filtration Rate and Serum C‐Reactive Protein Level to Overall Survival After Second‐Line Targeted Therapy Following Immuno‐Oncology Combination Therapy for Advanced Renal Cell Carcinoma

International Journal of Urology, EarlyView.
ABSTRACT Objectives Immune checkpoint inhibitor (ICI)‐based combination therapies are first‐line treatments for locally advanced or metastatic renal cell carcinoma (mRCC). However, second‐line treatment efficacy remains uncertain due to limited large randomized trials. This study evaluated real‐world oncological outcomes after second‐line treatments in
Keita Nakane, Hiromitsu Watanabe, Taku Naiki, Kiyoshi Takahara, Teruo Inamoto, Takahiro Yasui, Ryoichi Shiroki, Hideaki Miyake, Takuya Koie   +8 more
wiley   +1 more source

Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study. [PDF]

BMC Cancer
Song J, Sun X, Wang T, Li C, Yuan L.
europepmc   +1 more source

Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma

International Journal of Urology, EarlyView.
ABSTRACT Objectives The association between the response to first‐line chemotherapy and maintenance of avelumab remains unclear. We identified factors associated with the response to avelumab in patients with advanced urothelial carcinoma using real‐world data.
Satoshi Inoue, Akira Hayakawa, Mikinori Kobayashi, Yuriko Nagasaka, Takanao Omi, Noritoshi Shamoto, Fumihiro Ito, Takuma Yuba, Yuri Yuguchi, Hideji Kawanishi, Kosuke Tochigi, Shusuke Akamatsu   +11 more
wiley   +1 more source

MicroRNA-145 in urologic tumors: biological roles, regulatory networks, and clinical translation. [PDF]

Front Pharmacol
Gan L, Li W, Chen Q, Cheng L, Zhang F, Zhong H, Lu Y, Zheng L, Qian B.   +8 more
europepmc   +1 more source

Accuracy of cognitive vs software‐guided MRI‐targeted biopsy in predicting final grading at prostatectomy

BJU International, EarlyView.
Marco Finati, Anna Ricapito, Gennaro Musi, Bernardo Rocco, Francesco Porpiglia, Alessandro Antonelli, Paolo Gontero, Peter Bostrom, Luigi Schips, Giuseppe Simone, Vincenzo Mirone, Luca Carmignani, Giuseppe Mario Lodovico, Emanuele Montanari, Alessandro Sciarra, Pierluigi Bove, Ivan Jambor, Carlo Trombetta, Vincenzo Ficarra, Giuseppe Carrieri, Ugo Giovanni Falagario, PROMOD Working Group   +21 more
wiley   +1 more source

Impact of Impaired Renal Function on the Efficacy and Safety of Second‐Line Tyrosine Kinase Inhibitor Therapy After First‐Line Immuno‐Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study

International Journal of Urology, EarlyView.
ABSTRACT Objectives To evaluate the effects of renal impairment at the time of second‐line tyrosine kinase inhibitor (TKI) therapy initiation and rapid renal function decline during first‐line immuno‐oncology (IO) combination therapy on metastatic renal cell carcinoma (mRCC) patients treated with second‐line TKIs. Methods This multicenter retrospective
Naoki Fujita, Yuto Matsushita, Takahiro Kojima, Yukari Bando, Takahiro Osawa, Tomokazu Sazuka, Keisuke Goto, Kazuyuki Numakura, Kazutoshi Yamana, Shuya Kandori, Yoshihide Kawasaki, Takuma Kato, Makito Miyake, Kazutoshi Fujita, Kosuke Ueda, Hajime Tanaka, Ryotaro Tomida, Hiroshi Kitamura, Hideaki Miyake, Shingo Hakakeyama, on behalf of the Japanese Urological Oncology Group   +20 more
wiley   +1 more source

Assessing complications from retroperitoneal lymph node dissection for testicular cancer in North America. [PDF]

Can Urol Assoc J
Kailavasan M, de Jesus Cendejas-Gomez J, Huynh MJ, Inman BA, Power N.   +4 more
europepmc   +1 more source